Patients Advocate Seeks PTO Review of Wyeth’s Tygacil Patent

Generic Line
A patient advocacy group is using a recently created review pathway through the U.S. Patent and Trademark Office to challenge the patent on Wyeth’s antibiotic Tygacil outside a Hatch-Waxman ANDA.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00